Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Prototype Kit Diagnoses Visceral Leishmaniasis

By LabMedica International staff writers
Posted on 07 May 2013
A prototype direct agglutination test (DAT) kit for the laboratory diagnosis of visceral leishmaniasis (VL), called DAT-LPC, has been developed.

The diagnosis validity of this prototype DAT-LPC, which uses a freeze-dried antigen, was performed to evaluate the sensitivity and specificity of the assay.

Scientists at the Oswaldo Cruz Foundation (FIOCRUZ; Belo Horizonte, Brazil) took blood samples from 103 Brazilian patients with VL and 110 samples from patients with other parasitic infections, and healthy subjects. These samples were assayed with DAT-LPC and DAT-KIT (Royal Tropical Institute; Amsterdam, NL). Additionally, the results of 103 samples of VL patients based on two agglutination tests were correlated.

The DAT-LPC was incubated for four hours at room temperature; the end titer was read as the dilution immediately before the well with a clear sharp-edged blue spot identical in size to the reaction negative control. Appropriate negative and positive control samples with known DAT titers were included. The cut-off for interpretation of positive and negative results was 1:100. The DAT-LPC showed a sensitivity of 99.0%, specificity of 98.2% and diagnosis validity of 98.6%, which were similar to those found by the DAT-KIT. Moreover, there was positive correlation between the positive titers obtained by DAT-LPC and by DAT-KIT.

After six months of storage in an incubator at 40 °C and 75% moisture the DAT-LPC prototype remained stable. Physical aspects remained the same, and it produced consistent results with negative and positive samples assayed monthly. The authors concluded that the prototype kit showed high diagnostic accuracy and thermal stability; it is ready for use and could be transferred to industrial production. The DAT-LPC should replace the indirect immunofluorescent antibody test (IFAT) in routine serological tests for VL diagnosis in Brazil. It could be used in a complementary algorithm with immunochromatic dipstick tests, for different clinical scenarios and laboratorial settings. The study was published on February 3, 2013, in the journal Transactions of The Royal Society of Tropical Medicine and Hygiene.

Related Links:

Oswaldo Cruz Foundation
Royal Tropical Institute



New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.